ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down
AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.
Why it matters
Attributed market update with source link for portfolio context.